Literature DB >> 2892986

Beta-adrenergic blockers.

W H Frishman1.   

Abstract

beta-Adrenergic blocking drugs have been available for several years to treat ischemic heart disease and other cardiovascular and noncardiovascular disorders. There are multiple drugs in this class with various pharmacodynamic and pharmacokinetic properties that may be important in specific clinical situations and in avoiding certain adverse reactions. These drugs have been shown to be efficacious in relieving anginal symptoms and prolonging exercise tolerance, in reducing high blood pressure, for treating various arrhythmias, in therapy of hypertrophic cardiomyopathy, and for prolonging life in many survivors of acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2892986     DOI: 10.1016/s0025-7125(16)30786-6

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  18 in total

1.  Medical management of dissecting thoracic aneurysms.

Authors:  P J Hogan
Journal:  Tex Heart Inst J       Date:  1990

2.  Comparison of single-dose and steady-state nadolol plasma concentrations.

Authors:  J J Krukemyer; H Boudoulas; P F Binkley; J J Lima
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

Review 3.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 4.  Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.

Authors:  W H Frishman; E J Lazar; G Gorodokin
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 5.  Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy.

Authors:  Y Yamada; K Matsuyama; K Ito; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

Review 6.  Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?

Authors:  David M Lang
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

Review 7.  Profile of an ideal antianginal agent.

Authors:  E J Lazar; W H Frishman
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 8.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 9.  Novel approaches to the treatment of cocaine addiction.

Authors:  Mehmet Sofuoglu; Thomas R Kosten
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 10.  Drug-induced orthostatic hypotension.

Authors:  J A Schoenberger
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.